REYON Pharmaceutical Statistics

Total Valuation

KRX:102460 has a market cap or net worth of KRW 205.42 billion. The enterprise value is 399.26 billion.

Market Cap	205.42B
Enterprise Value	399.26B

Important Dates

The next estimated earnings date is Wednesday, May 14, 2025.

Earnings Date	May 14, 2025
Ex-Dividend Date	n/a

Share Statistics

KRX:102460 has 18.34 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	18.34M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	81.15%
Owned by Institutions (%)	3.73%
Float	2.96M

Valuation Ratios

The trailing PE ratio is 49.56.

PE Ratio	49.56
Forward PE	n/a
PS Ratio	1.39
PB Ratio	0.82
P/TBV Ratio	0.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	96.18
EV / Sales	2.69
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-22.88

Financial Position

The company has a current ratio of 0.66, with a Debt / Equity ratio of 0.82.

Current Ratio	0.66
Quick Ratio	0.35
Debt / Equity	0.82
Debt / EBITDA	38.08
Debt / FCF	-11.70
Interest Coverage	-0.79

Financial Efficiency

Return on equity (ROE) is 1.67% and return on invested capital (ROIC) is -0.13%.

Return on Equity (ROE)	1.67%
Return on Assets (ROA)	-0.12%
Return on Invested Capital (ROIC)	-0.13%
Return on Capital Employed (ROCE)	-0.27%
Revenue Per Employee	331.03M
Profits Per Employee	9.27M
Employee Count	448
Asset Turnover	0.30
Inventory Turnover	1.99

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.06% in the last 52 weeks. The beta is 0.90, so KRX:102460's price volatility has been lower than the market average.

Beta (5Y)	0.90
52-Week Price Change	-16.06%
50-Day Moving Average	11,825.20
200-Day Moving Average	13,434.00
Relative Strength Index (RSI)	49.44
Average Volume (20 Days)	28,572

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KRX:102460 had revenue of KRW 148.30 billion and earned 4.15 billion in profits. Earnings per share was 226.00.

Revenue	148.30B
Gross Profit	71.69B
Operating Income	-985.46M
Pretax Income	5.16B
Net Income	4.15B
EBITDA	5.36B
EBIT	-985.46M
Earnings Per Share (EPS)	226.00

Full Income Statement

Balance Sheet

The company has 10.21 billion in cash and 204.05 billion in debt, giving a net cash position of -193.84 billion or -10,568.57 per share.

Cash & Cash Equivalents	10.21B
Total Debt	204.05B
Net Cash	-193.84B
Net Cash Per Share	-10,568.57
Equity (Book Value)	249.94B
Book Value Per Share	13,627.46
Working Capital	-46.09B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.44 billion and capital expenditures -16.01 billion, giving a free cash flow of -17.45 billion.

Operating Cash Flow	-1.44B
Capital Expenditures	-16.01B
Free Cash Flow	-17.45B
FCF Per Share	-951.29

Full Cash Flow Statement

Margins

Gross margin is 48.34%, with operating and profit margins of -0.66% and 2.80%.

Gross Margin	48.34%
Operating Margin	-0.66%
Pretax Margin	3.48%
Profit Margin	2.80%
EBITDA Margin	3.61%
EBIT Margin	-0.66%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 1.34%.

Dividend Per Share	150.00
Dividend Yield	1.34%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	66.27%
Buyback Yield	n/a
Shareholder Yield	1.34%
Earnings Yield	2.02%
FCF Yield	-8.49%

Dividend Details

Stock Splits

The last stock split was on December 29, 2020. It was a forward split with a ratio of 1.02.

Last Split Date	Dec 29, 2020
Split Type	Forward
Split Ratio	1.02

Scores

KRX:102460 has an Altman Z-Score of 1.4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.4
Piotroski F-Score	n/a